1. Introduction {#sec1}
===============

Hypertension is a common chronic condition which is associated with various complications including cardiovascular disease and chronic kidney disease. It remains that hypertension is one of the most important preventable conditions to reduce cardiovascular mortality \[[@B1]\]. Despite this, the high and increasing prevalence of hypertension still contributes to considerable socioeconomic burden globally \[[@B2]--[@B4]\].

In order to choose the appropriate antihypertensive drug among various available classes, several factors should be considered, such as age and underlying comorbid conditions \[[@B5]--[@B7]\]. Also, the type of antihypertensive drugs can affect prescribing patterns as well as drug compliance \[[@B8]--[@B11]\]. Therefore, it is necessary to assess prescription patterns to determine whether current prescription is reasonable, evidence-based, and cost-effective \[[@B11]\]. Although there have been several studies on prescription patterns of antihypertensives in other countries, they are not relevant in the Korean context since prescription patterns are influenced by time and region \[[@B9],[@B10],[@B12]--[@B14]\]. Furthermore, previously conducted studies in Korea are either too old or not representative (single hospital-based study) \[[@B15], [@B16]\].

This study aimed at evaluating prescribing patterns of antihypertensive drugs in patients who were prescribed antihypertensive drugs for the first time.

2. Materials and Methods {#sec2}
========================

2.1. Data Sources {#sec2.1}
-----------------

The claims data of the Korean National Health Insurance Research Database (NHIRD) were analyzed. NHIRD contains qualification data, medical services claim data, and pharmacy claim data. As such, the claims data include patient information such as age, sex, household income, residential regions, as well as diagnosis information (by the International Classification of Diseases, 10th Revision; ICD-10) and specific information of diagnostic tests, procedures, and prescriptions.

In general, the Korean National Health Insurance Service (NHIS) is the sole insurer providing a mandatory universal health insurance which virtually covers the entire Korean population (about 97% of total population) and a medical aid program to those in the lowest income bracket who are covered by government funding. We used the nation-wide claims data which covered the South Korean population over a 5-year period, from 1 January 2011 to 31 December 2015. Detailed insights into the advantages of this data are described elsewhere \[[@B17], [@B18]\].

2.2. Study Population {#sec2.2}
---------------------

From the whole Korean population (*N* = ∼50 million), patients who were newly diagnosed with hypertension (ICD-10: I10, I11, I12, I13, or I15) and prescribed with antihypertensive agents were included in this study. We further confirmed that the study subjects did not have any previous record of antihypertensive medication during the prior 12 months.

2.3. Variables {#sec2.3}
--------------

### 2.3.1. Antihypertensive Agents {#sec2.3.1}

Antihypertensive agents were classified into 5 major categories, including angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACEi), calcium channel blockers (CCB), beta-blockers (BB), and thiazide diuretics (including indapamide and chlorthalidone), or other antihypertensive drugs.

Initial prescription was divided into single drug and combination. Single drug was defined as the prescription of 1 class of antihypertensive at first prescription. Combination was defined as prescription of 2 or more classes of antihypertensives at first prescription and was further categorized by single-pill fixed-dose drug and free combination (multiple-pill combinations). Commonly used combinations available commercially are specifically listed: ARB + CCB, ARB + thiazide, and ARB + CCB + thiazide.

### 2.3.2. Comorbidities {#sec2.3.2}

Comorbidities were defined by ICD 10 codes: diabetes (ICD 10: E11-14), dyslipidemia (E78), congestive heart failure (I50), coronary heart disease(I20-25), stroke (I60 to I64, I67, and I69), chronic kidney disease (N18), and cancer (CX) during the previous 1 year prior to index date (first prescription of antihypertensive medication). The Charlson comorbidity index was also assessed in the same manner \[[@B16]\].

2.4. Statistical Analyses {#sec2.4}
-------------------------

The baseline characteristics of hypertensive patients who were newly prescribed with antihypertensive medication were described using frequencies and percentages or as means with standard deviation.

Descriptive statistics were calculated for patterns of first prescriptions of antihypertensive medications. The proportion of each antihypertensive class was calculated according to patient characteristics (age, sex, income level, and place of residence), medical characteristics (the Charlson comorbidity index and each comorbidity as defined above), provider characteristics (level of hospital; general hospital vs. hospital vs. clinic), and year of first prescription.

Factors associated with choice of first prescription for hypertension were investigated with a series of multivariate logistic regression analyses including all of the aforementioned characteristics. Outcomes were (1) combination vs. single, (2) choice of each drug class among single drug user (exclusive to each other), (3) choice of each drug class among all patients (not exclusive to each other), and (4) fixed-dose combination vs. free combination for selected combinations. Also, the trends of combination therapy according to the age group, income level, and Charlson\'s comorbidity index were assessed by calculating the "*p* for trend."

All analyses were performed using the SAS statistical software (ver. 9.3, SAS Institute., Cary, NC, USA). All tests were two-sided, and statistical significance was defined as a *p* value \<0.05.

2.5. Ethics Statement {#sec2.5}
---------------------

This study was reviewed and approved by the Institutional Review Board of the Samsung Medical Center (IRB No. SMC 2007-07-130). The requirement for informed consent was waived because this study is based on routinely collected administrative or claims data.

3. Results {#sec3}
==========

3.1. Baseline Characteristics {#sec3.1}
-----------------------------

A total of 2,919,162 subjects had started taking antihypertension medications during the study period. 56.0% of these were male patients. The mean age of the study population was 53.0 (±14.5) years. Over half of the study population resided in metropolitan areas. About 67.9% of subjects had 1 or more comorbidity as per the Charlson comorbidity index. Subjects had various hypertension-related comorbid conditions such as dyslipidemia (27.6%), coronary heart disease (13.8%), diabetes (12.7%), stroke, (4.6%), congestive heart failure (4.1%), and chronic kidney disease (0.93%). The annual incidence rate per year was 1.24% in 2011, 1.20% in 2012, 1.13% in 2013, 1.05% in 2014, and 1.12% in 2015, respectively ([Table 1](#tab1){ref-type="table"}).

3.2. Frequency and Trend of the Prescription {#sec3.2}
--------------------------------------------

Around two-thirds of the study population was prescribed with monotherapy at first prescription, and one-third was prescribed with initial combination therapy ([Table 2](#tab2){ref-type="table"}). CCB was the most frequently prescribed monotherapy drug (25.70%), followed by ARB (24.45%) and BB (11.88%). The proportion of ARB and BB prescriptions increased during the study period, while CCB and ACEI decreased. The ARB + CCB was the most frequently prescribed combination (12.59%) and was found to be increasing, while ARB + thiazide (9.79%) was decreasing during the study period ([Table 3](#tab3){ref-type="table"}). Among the 5 drug classes, ARB was the most frequently prescribed drug (51.61%), followed by CCB (45.03%), BB (18.48%), thiazide diuretics (17.01%), and ACEi (3.11%). Initial drug choice differed by comorbidities, e.g., 64.74% of diabetes patients initiated with ARB, while 54.18% of CHF patients were initiated with beta-blockers. In CKD patients, 59.82% received ARB and 8.34% received ACEi ([Table 4](#tab4){ref-type="table"}).

A comparison of prescription rates between 2011 and 2015 revealed an increase of 4% in the prescription rate of ARB and an 8% increase in the rate of thiazide prescription ([Figure 1](#fig1){ref-type="fig"}).

3.3. Trend of Single-Pill Fixed-Dose Combination {#sec3.3}
------------------------------------------------

Among combination therapy users, most patients were prescribed a single-pill fixed-dose combination (83.73% for ARB + CCB and 96.46% for ARB + thiazide, respectively) in an increasing proportion during the study period ([Table 3](#tab3){ref-type="table"}).

3.4. Trend and Factors Associated with Initial Combination Therapy {#sec3.4}
------------------------------------------------------------------

Female patients were less likely to be prescribed with combination therapy at first prescription (adjusted odds ratio: 0.764, 95% CI 0.760--0.768). Having congestive heart failure, dyslipidemia, CHD, stroke, CKD, and cancer was slightly associated with initiation with combination therapy, while it was opposite with diabetes mellitus. Primary clinics prescribed combination antihypertensive drugs more frequently than secondary hospitals and general hospitals. Initial combination therapy decreased slightly during the study period (35.81 in year 2011 to 32.53% in year 2015). There was no significant trend by the age group or Charlson comorbidity index ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, physicians\' prescription patterns of antihypertensive drugs for treatment-naïve patients were identified using the National Health Insurance claims data. The strength of this study is its generalizability, as it uses claims data collected from the entire South Korean population and assess data over a 5-year period which allows for the identification of trends in prescription patterns.

In a previous study of prescription patterns in Korea conducted in 2009, CCB was the most frequently prescribed antihypertensive (64.4%), followed by diuretics (44.6%), ARB (33.3%), BB (21.6%), and ACEi (11.7%) \[[@B16]\]. In this study, the corresponding figures were 45.0%, 17.0%, 51.6%, 18.5%, and 3.1%, respectively. This shows that the use of ARB has significantly increased over time, while use of other antihypertensive classes decreased.

Similarly, we also identified that the use of thiazide diuretics and ACEi was decreasing and ARB use was increasing during the study period. Although CCB was the most frequently prescribed drug for monotherapy, overall ARB was the most frequently prescribed class of antihypertensive drugs since the prescription of ARB for combination therapy also increased.

The prescription of CCBs and ARBs increased worldwide over the past several years \[[@B11]\]. Especially, CCBs and ARBs were the most frequently prescribed antihypertensives in the nearby countries of Japan and China \[[@B19], [@B20]\]. There may be several reasons for this changing prescription trend. The former JNC7 recommended diuretics as the first-line therapy \[[@B6], [@B21]\], but recent guidelines including regional Korean guidelines announced not only diuretics but also ARBs and CCBs as the first-line treatment, and the corresponding drug utilization appears to have changed \[[@B5], [@B7], [@B22], [@B23]\]. Moreover, although these guidelines included the diuretics as first-line drugs, in East Asian countries including Japan and China, the prescription rate of diuretics for hypertension is lower than that in the United States \[[@B19], [@B20], [@B24]\]. Frequent adverse events with the use of diuretics and associated low compliance may account for the low prescription rate \[[@B12], [@B19]\]. Also, relatively low ACEi prescription presumably reflects the occurrence of frequent side effects in the Asian population such as dry cough \[[@B25]\]. The decreased use of ACEi might account for the increased use of the alternative drug, the ARB. In addition, more favorable adherence and less frequent side effects might increase the use of ARB \[[@B12]\]. Lim et al. had already reported the increase in prescriptions for ARBs and a decrease for diuretics in Korea \[[@B15]\]. However, as the study was based on a single tertiary hospital, the results cannot be generalized to the overall population. Moreover, the study included patients who were already taking antihypertensives, so the proportion of combination therapy was higher than that of the present study (50.9% vs. 33.3%). Although the prescription patterns of antihypertensives differ across countries \[[@B11], [@B19], [@B20]\], the proportion of initial combination therapy of the present study seems to be low when compared to nearby countries \[[@B26]\]. Because intensive initial treatment for hypertension is recommended nowadays, an effort to increase the proportion of initial combination therapy may be warranted \[[@B5], [@B27]\]. Considering patient compliance, a single-pill, fixed-dose combination is a good option \[[@B28]\].

In some groups, other classes rather than CCBs or ARBs were prescribed frequently. In those less than 20 years of age, the use of ACEi and BBs was more frequent. However, it is unclear why ACEi and BBs were used more frequently than in other age groups. Certain underlying conditions such as diabetes, proteinuria, or migraines as well as physician\'s preference considering adverse drug effects may affect the prescription pattern in children and adolescents \[[@B29], [@B30]\]. Although several guidelines excluded beta-blocker as a first-line antihypertensive drug \[[@B5], [@B7]\], the prescription rate of the drug was relatively stable during the study period. It may be due to the presence of comorbid conditions such as ischemic heart disease and arrhythmia, in which the use of beta-blockers is inevitable. However, overall beta-blocker use was found to be relatively low. Unlike the JNC 7 guideline, the JNC 8 guideline did not suggest compelling indications of each antihypertensive drug classes. However, there are several clinical situations which make a specific antihypertensive class preferred to others. For example, JNC 7 and domestic hypertension guidelines in Korea recommend beta-blocker as an initial choice for hypertension in congestive heart failure patients \[[@B16]\]. Therefore, unlike other conditions, beta-blocker may be most frequently prescribed for congestive heart failure patients in the present study, suggesting that clinical guidelines are reflected in prescription of Korean physicians.

On the contrary, we also observed some gaps between the guidelines and clinical practice. According to the JNC 8 guideline, the use of ARB or ACEi was recommended especially in those with chronic kidney diseases \[[@B7]\]. However, the prescription rate of ARB or ACEi in the chronic kidney disease patients was not optimal and was only 68.2%. Even though there can be rational reasons not to use these drugs, a substantial portion of chronic kidney disease patients may lose the chance to prevent or delay disease progression. Doctors often prescribe drugs according to prescription patterns based on their own experience rather than scientific evidences \[[@B11]\]. Further studies are needed to assess and decrease these gaps of prescription pattern.

Overall, the prescription rate of combination therapy was slightly decreasing throughout the study period. In JNC 8 guideline, patients with stage 2 hypertension (BP \> 160/100) are recommended to receive combination therapy from the first prescription \[[@B7]\]. In Korea, the national health screening program is offered biennially and more hypertension is diagnosed at an earlier stage due to increasing participation rates \[[@B31]\]. However, considering the relatively low proportion of patients achieving the target blood pressure level (less than 70%) \[[@B32]\], more aggressive treatment for hypertensive patients using combination therapy is warranted.

For initial combination therapy, most patients received single-pill fixed-dose combination drugs and this was an increasing trend. The use of single-pill fixed-dose combination is advantageous in terms of the price of a single-pill combination and the advantage of drug adherence and blood pressure control \[[@B6], [@B7], [@B11], [@B33]\], suggesting a trend toward the favorable prescription pattern.

There are several limitations to be considered in this study. First, there is possibility of false claims of hypertension for reimbursement purpose. For example, beta-blockers are often effective in chronic headache but not reimbursed in Korea for that purpose. So, the physician might have entered the hypertension disease code for making the drug covered by the NHI. Second, we do not have detailed clinical information for each prescription and could not determine the appropriateness of drug choice in individual basis.

5. Conclusions {#sec5}
==============

We identified overall prescription patterns of antihypertensives for treatment-naïve patients in South Korea. The findings can lead to a rational, evidence-based, and cost-effective improvement of prescription patterns in newly diagnosed hypertensive patients.
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###### 

Baseline characteristics of newly diagnosed hypertension patients (total *n* = 2,919,162)

                                          *n*         \%
  --------------------------------------- ----------- -------
  Age                                                  
   \<20                                   45,222      1.55
   20--29                                 95,489      3.27
   30--39                                 303,523     10.40
   40--49                                 713,524     24.44
   50--59                                 866,370     29.68
   60--69                                 508,662     17.42
   70--79                                 294,771     10.10
   ≥80                                    91,601      3.14
  Sex                                                  
   Male                                   1,633,768   55.97
   Female                                 1,285,394   44.03
  Income                                               
   Medical aid                            112,217     3.84
   Q1 (low)                               766,378     26.25
   Q2                                     696,643     23.86
   Q3                                     663,524     22.73
   Q4 (high)                              680,400     23.31
  Residence                                            
   Metropolitan                           1,741,304   59.65
   City                                   833,767     28.56
   Rural                                  344,091     11.79
  Charlson comorbidity index                           
   0                                      938,134     32.14
   1                                      791,388     27.11
   2                                      497,523     17.04
   ≥3                                     692,117     23.71
  Provider type                                        
   General hospital                       924,592     31.67
   Hospital                               330,928     11.34
   Clinic                                 1,560,700   53.46
   Others (public health centers, etc.)   102,942     3.53
  Comorbidity                                          
   Diabetes                               371,477     12.73
   Dyslipidemia                           806,246     27.62
   Congestive heart failure               120,749     4.14
   Ischemic heart failure                 401,547     13.76
   Stroke                                 135,569     4.64
   Chronic kidney disease                 27,263      0.93
   Cancer                                 44,626      1.53
  Year of diagnosis                                    
   2011                                   627,249     21.49
   2012                                   597,912     20.48
   2013                                   578,479     19.82
   2014                                   538,468     18.45
   2015                                   577,054     19.77

###### 

Prescription pattern by the number of drug classes, *n* (%).

                                  Single drug class   Combination       Combination (vs. single)
  ------------------------------- ------------------- ----------------- --------------------------
                                                                        OR (95% CI)
  Overall                         1,947,796 (66.72)   971366 (33.28)     
  Age (mean ± SD)                 53.13 ± 14.48       52.84 ± 14.52      
   \<20                           29,435 (65.09)      15,787 (34.91)    1.214 (1.190--1.239)
   20--29                         72,099 (75.51)      23,390 (24.49)    0.650 (0.640--0.661)
   30--39                         202,994 (66.88)     100,529 (33.12)   0.957 (0.948--0.965)
   40--49                         458,093 (64.2)      255,431 (35.8)    1.094 (1.087--1.101)
   50--59                         574,198 (66.28)     292,172 (33.72)   1 (ref.)
   60--69                         348,811 (68.57)     159,851 (31.43)   0.900 (0.894--0.907)
   70--79                         202,102 (68.56)     92,669 (31.44)    0.913 (0.905--0.922)
   ≥80                            60,064 (65.57)      31,537 (34.43)    1.041 (1.026--1.057)
  Sex                                                                    
   Male                           1,048,973 (64.21)   584,795 (35.79)   1 (ref.)
   Female                         898,823 (69.93)     386,571 (30.07)   0.764 (0.760--0.768)
  Income                                                                 
   Medical aid                    75,202 (67.01)      37,015 (32.99)    1.133 (1.118--1.149)
   Q1(Low)                        499,304 (65.15)     267,074 (34.85)   1.220 (1.212--1.229)
   Q2                             457,765 (65.71)     238,878 (34.29)   1.184 (1.175--1.193)
   Q3                             444,104 (66.93)     219,420 (33.07)   1.115 (1.107--1.123)
  Q4(High)                        471,421 (69.29)     208,979 (30.71)   1 (ref.)
  Residence                                                              
   Metropolitan                   1,172,041 (67.31)   569,263 (32.69)   1 (ref.)
   City                           549,150 (65.86)     284,617 (34.14)   1.068 (1.062--1.074)
   Rural                          226,605 (65.86)     117,486 (34.14)   1.077 (1.069--1.086)
  Charlson\'s comorbidity index                                          
   0                              616,812 (65.75)     321,322 (34.25)   1.050 (1.041--1.058)
   1                              531,229 (67.13)     260,159 (32.87)   0.999 (0.992--1.007)
   2                              338,054 (67.95)     159,469 (32.05)   0.962 (0.955--0.970)
   ≥3                             461,701 (66.71)     230,416 (33.29)   1 (ref.)
  Comorbidity                                                            
   Diabetes                       258,962 (69.71)     112,515 (30.29)   0.816 (0.810--0.823)
   Dyslipidemia                   528,199 (65.51)     278,047 (34.49)   1.107 (1.101--1.114)
   Congestive heart failure       65,091 (53.91)      55,658 (46.09)    1.890 (1.867--1.914)
   Ischemic heart failure         257,083 (64.02)     144,464 (35.98)   1.132 (1.123--1.140)
   Stroke                         87,896 (64.83)      47,673 (35.17)    1.141 (1.128--1.155)
   Chronic kidney disease         17,263 (63.32)      10,000 (36.68)    1.193 (1.163--1.224)
   Cancer                         29,331 (65.73)      15,295 (34.27)    1.177 (1.153--1.201)
  Provider type                                                          
   General hospital               641,364 (69.37)     283,228 (30.63)   0.767 (0.763--0.772)
   Hospital                       216,869 (65.53)     114,059 (34.47)   0.964 (0.956--0.971)
   Clinic                         1019,985 (65.35)    540,715 (34.65)   1 (ref.)
   Other                          69,578 (67.59)      33,364 (32.41)    0.900 (0.888--0.913)
  Year of diagnosis                                                      
   2011                           402,660 (64.19)     224,589 (35.81)   1 (ref.)
   2012                           395,541 (66.15)     202,371 (33.85)   0.915 (0.909--0.922)
   2013                           395,450 (68.36)     183,029 (31.64)   0.824 (0.818--0.831)
   2014                           364,782 (67.74)     173,686 (32.26)   0.843 (0.837--0.850)
   2015                           389,363 (67.47)     187,691 (32.53)   0.850 (0.843--0.856)

OR: odds ratio; CI: confidence interval.

###### 

Prescription pattern of antihypertensive monotherapy and combination therapy, *n* (%).

                               Monotherapy       Combination therapy                                                                                                                                                                
  ---------------------------- ----------------- --------------------- ----------------- ----------------- --------------- ----------------- ----------------- ----------------- ----------------- --------------- ---------------- -----------------
                               713,667 (24.45)   44,406 (1.52)         346,673 (11.88)   750,337 (25.70)   92,713 (3.18)   367,572 (12.59)   307,781 (83.73)   285,869 (9.79)    275,746 (96.46)   40,691 (1.39)   38,083 (93.59)   277,234 (9.50)
  Age (mean ± SD)              52.86 ± 12.61     50.34 ± 19.56         49.32 ± 16.68     55.37 ± 13.96     52.69 ± 16.7    51.96 ± 12.56     51.47 ± 12.22     53.99 ± 12.52     53.84 ± 12.41     53.67 ± 13.3    53.8 ± 13.28     52.68 ± 18.43
   \<20                        4,492 (9.93)      4,600 (10.17)         13,417 (29.67)    4,786 (10.58)     2,140 (4.73)    1,227 (2.71)      971 (79.14)       534 (1.18)        510 (95.51)       86 (0.19)       74 (86.05)       13,940 (30.83)
   20--29                      15,365 (16.09)    1,681 (1.76)          30,155 (31.58)    18,757 (19.64)    6,141 (6.43)    8,426 (8.82)      7,083 (84.06)     4,454 (4.66)      4,279 (96.07)     830 (0.87)      747 (90.00)      9,680 (10.14)
   30--39                      72,328 (23.83)    4,051 (1.33)          48,706 (16.05)    66,834 (22.02)    11,075 (3.65)   43,945 (14.48)    37,796 (86.01)    25,751 (8.48)     24,977 (96.99)    4,304 (1.42)    3,981 (92.50)    26,529 (8.74)
   40--49                      194,938 (27.32)   8,606 (1.21)          75,324 (10.56)    160,178 (22.45)   19,047 (2.67)   109,288 (15.32)   94,415 (86.39)    77,024 (10.79)    74,997 (97.37)    11,147 (1.56)   10,387 (93.18)   57,972 (8.12)
   50--59                      229,509 (26.49)   10,949 (1.26)         87,726 (10.13)    222,731 (25.71)   23,283 (2.69)   114,792 (13.25)   97,355 (84.81)    91,574 (10.57)    88,931 (97.11)    12,316 (1.42)   11,522 (93.55)   73,490 (8.48)
   60--69                      122,171 (24.02)   7,423 (1.46)          52,154 (10.25)    152,145 (29.91)   14,918 (2.93)   54,608 (10.74)    44,390 (81.29)    51,040 (10.03)    49,072 (96.14)    6,527 (1.28)    6,157 (94.33)    47,676 (9.37)
   70--79                      60,175 (20.41)    5,136 (1.74)          30,672 (10.41)    94,567 (32.08)    11,552 (3.92)   26,871 (9.12)     20,214 (75.23)    28,025 (9.51)     26,273 (93.75)    3,947 (1.34)    3,749 (94.98)    33,826 (11.48)
   ≥80                         14,689 (16.04)    1,960 (2.14)          8,519 (9.30)      30,339 (33.12)    4,557 (4.97)    8,415 (9.19)      5,557 (66.04)     7,467 (8.15)      6,707 (89.82)     1,534 (1.67)    1,466 (95.57)    14,121 (15.42)
  Sex                                                                                                                                                                                                                                
   Male                        420,813 (25.76)   27,129 (1.66)         155,995 (9.55)    417,782 (25.57)   27,254 (1.67)   238,220 (14.58)   200,266 (84.07)   157,969 (9.67)    153,329 (97.06)   25,404 (1.55)   23,701 (93.30)   163,202 (9.99)
   Female                      292,854 (22.78)   17,277 (1.34)         190,678 (14.83)   332,555 (25.87)   65,459 (5.09)   129,352 (10.06)   107,515 (83.12)   127,900 (9.95)    122,417 (95.71)   15,287 (1.19)   14,382 (94.08)   114,032 (8.87)
  Income                                                                                                                                                                                                                             
   Medical aid                 21,158 (18.85)    1,963 (1.75)          19,159 (17.07)    27,747 (24.73)    5,175 (4.61)    10,888 (9.70)     8,507 (78.13)     8,903 (7.93)      8,405 (94.41)     1,477 (1.32)    1,409 (95.40)    15,747 (14.03)
   Q1(low)                     179,546 (23.43)   10,688 (1.39)         87,246 (11.38)    196,925 (25.70)   24,899 (3.25)   100,997 (13.18)   84,407 (83.57)    78,733 (10.27)    75,970 (96.49)    12,159 (1.59)   11,381 (93.60)   75,185 (9.81)
   Q2                          167,807 (24.09)   10,021 (1.44)         81,121 (11.64)    176,271 (25.30)   22,545 (3.24)   91,692 (13.16)    77,146 (84.14)    69,714 (10.01)    67,372 (96.64)    10,238 (1.47)   9,573 (93.50)    67,234 (9.65)
   Q3                          166,039 (25.02)   10,571 (1.59)         75,841 (11.43)    171,715 (25.88)   19,938 (3.00)   83,991 (12.66)    70,344 (83.75)    65,496 (9.87)     63,175 (96.46)    9,085 (1.37)    8,512 (93.69)    60,848 (9.17)
   Q4 (high)                   179,117 (26.33)   11,163 (1.64)         83,306 (12.24)    177,679 (26.11)   20,156 (2.96)   80,004 (11.76)    67,377 (84.22)    63,023 (9.26)     60,824 (96.51)    7,732 (1.14)    7,208 (93.22)    58,220 (8.56)
  Residence                                                                                                                                                                                                                          
   Metropolitan                441,925 (25.38)   25,693 (1.48)         208,988 (12.00)   443,462 (25.47)   51,973 (2.98)   222,839 (12.80)   189,878 (85.21)   165,196 (9.49)    159,935 (96.82)   22,894 (1.31)   21,283 (92.96)   158,334 (9.09)
   City                        198,002 (23.75)   12,818 (1.54)         100,108 (12.01)   210,123 (25.20)   28,099 (3.37)   106,064 (12.72)   87,828 (82.81)    84,793 (10.17)    81,631 (96.27)    12,440 (1.49)   11,738 (94.36)   81,320 (9.75)
   Rural                       73,740 (21.43)    5,895 (1.710)         37,577 (10.92)    96,752 (28.12)    12,641 (3.67)   38,669 (11.24)    30,075 (77.78)    35,880 (10.43)    34,180 (95.26)    5,357 (1.56)    5,062 (94.49)    37,580 (10.92)
  Charlson comorbidity index                                                                                                                                                                                                         
   0                           223,380 (23.81)   7,532 (0.80)          102,265 (10.90)   259,791 (27.69)   23,844 (2.54)   144,663 (15.42)   126,841 (87.68)   101,639 (10.83)   99,032 (97.44)    14,243 (1.52)   13,245 (92.99)   60,777 (6.48)
   1                           194,677 (24.60)   9,554 (1.21)          93,931 (11.87)    206,751 (26.13)   26,316 (3.33)   101,812 (12.86)   86,629 (85.09)    81,253 (10.27)    78,628 (96.77)    11,177 (1.41)   10,490 (93.85)   65,917 (8.33)
   2                           125,456 (25.22)   9,257 (1.86)          61,032 (12.27)    124,275 (24.98)   18,034 (3.62)   55,255 (11.11)    45,584 (82.50)    47,316 (9.51)     45,392 (95.93)    6,542 (1.31)    6,118 (93.52)    50,356 (10.12)
   ≥3                          170,154 (24.58)   18,063 (2.61)         89,445 (12.92)    159,520 (23.05)   24,519 (3.54)   65,842 (9.51)     48,727 (74.01)    55,661 (8.04)     52,694 (94.67)    8,729 (1.26)    8,230 (94.28)    100,184 (14.48)
  Comorbidity                                                                                                                                                                                                                        
   Diabetes                    146,705 (39.49)   12,888 (3.47)         26,869 (7.23)     65,253 (17.57)    7,247 (1.95)    39,243 (10.56)    31,441 (80.12)    35,983 (9.69)     34,825 (96.78)    4,397 (1.18)    4,140 (94.16)    32,892 (8.85)
   Dyslipidemia                240,239 (29.80)   17,020 (2.11)         77,673 (9.63)     176,764 (21.92)   16,503 (2.05)   97,247 (12.06)    79,833 (82.09)    78,273 (9.71)     75,288 (96.19)    10,327 (1.28)   9,564 (92.61)    92,200 (11.44)
   Congestive heart failure    14,337 (11.87)    5,768 (4.78)          26,936 (22.31)    14,183 (11.75)    3,867 (3.20)    6,022 (4.99)      3,569 (59.27)     5,859 (4.85)      4,705 (80.30)     964 (0.80)      908 (94.19)      42,813 (35.46)
   Ischemic heart failure      58,176 (14.49)    9,904 (2.47)          81,919 (20.40)    99,718 (24.83)    7,366 (1.83)    30,283 (7.54)     19,567 (64.61)    19,949 (4.97)     18,447 (92.47)    4,467 (1.11)    4,238 (94.87)    89,765 (22.35)
   Stroke                      31,015 (22.88)    2,857 (2.11)          15,783 (11.64)    34,864 (25.72)    3,377 (2.49)    14,745 (10.88)    9,600 (65.11)     8,295 (6.12)      7,727 (93.15)     2,235 (1.65)    2,075 (92.84)    22,398 (16.52)
   Chronic kidney disease      8,793 (32.25)     1,102 (4.04)          1,694 (6.21)      5,072 (18.60)     602 (2.21)      3,088 (11.33)     1,769 (57.29)     1,441 (5.29)      1,297 (90.01)     344 (1.26)      324 (94.19)      5,127 (18.81)
   Cancer                      5,652 (12.67)     651 (1.46)            6,097 (13.66)     16,004 (35.86)    927 (2.08)      3,526 (7.90)      2,498 (70.85)     2,073 (4.65)      1,963 (94.69)     421 (0.94)      400 (95.01)      9,275 (20.78)
  Provider type                                                                                                                                                                                                                      
   General hospital            170,474 (18.44)   27,923 (3.02)         188,819 (20.42)   226,705 (24.52)   27,443 (2.97)   85,950 (9.30)     60,437 (70.32)    25,458 (2.75)     22,832 (89.68)    7,785 (0.84)    6,939 (89.13)    164,035 (17.74)
   Hospital                    64,955 (19.63)    3,981 (1.20)          38,207 (11.55)    99,156 (29.96)    10,570 (3.19)   50,126 (15.15)    40,075 (79.95)    26,565 (8.03)     25,504 (96.01)    7,847 (2.37)    7,645 (97.43)    29,521 (8.92)
   Clinic                      457,721 (29.33)   10,968 (0.70)         116,359 (7.46)    382,965 (24.54)   51,972 (3.33)   217,934 (13.96)   197,185 (90.48)   223,409 (14.31)   21,7378 (97.3)    22,652 (1.45)   21,151 (93.37)   76,720 (4.92)
   Others                      20,517 (19.93)    1,534 (1.49)          3,288 (3.19)      41,511 (40.32)    2,728 (2.65)    13,562 (13.17)    10,084 (74.35)    10,437 (10.14)    10,032 (96.12)    2,407 (2.34)    2,348 (97.55)    6,958 (6.76)
  Year                                                                                                                                                                                                                               
   2011                        133,122 (21.22)   11,086 (1.77)         69,095 (11.02)    169,958 (27.10)   19,399 (3.09)   67,370 (10.74)    51,975 (77.15)    74,967 (11.95)    71,990 (96.03)    12,913 (2.06)   12,913 (100)     69,339 (11.05)
   2012                        142,023 (23.75)   10,293 (1.72)         70,719 (11.83)    153,033 (25.59)   19,473 (3.26)   62,141 (10.39)    48,491 (78.03)    69,941 (11.7)     67,656 (96.73)    10,217 (1.71)   10,217 (100)     60,072 (10.05)
   2013                        150,777 (26.06)   9,248 (1.60)          68,405 (11.82)    148,626 (25.69)   18,394 (3.18)   68,945 (11.92)    56,772 (82.34)    55,487 (9.59)     53,536 (96.48)    7,025 (1.21)    6,597 (93.91)    51,572 (8.92)
   2014                        136,533 (25.36)   7,415 (1.38)          68,083 (12.64)    134,755 (25.03)   17,996 (3.34)   79,351 (14.74)    70,132 (88.38)    42,131 (7.82)     40,626 (96.43)    5,123 (0.95)    4,319 (84.31)    47,081 (8.74)
   2015                        151,212 (26.20)   6,364 (1.10)          70,371 (12.19)    143,965 (24.95)   17,451 (3.02)   89,765 (15.56)    80,411 (89.58)    43,343 (7.51)     41,938 (96.76)    5,413 (0.94)    4,037 (74.58)    49,170 (8.52)

###### 

Prescription pattern by the drug classes, either included in monotherapy or combination therapy, *n* (%).

                               ARB                ACEI             BETA              CCB                 Diuretics
  ---------------------------- ------------------ ---------------- ----------------- ------------------- -----------------
  Overall                      150,6561 (51.61)   90,784 (3.11)    539,372 (18.48)   1,314,597 (45.03)   496,634 (17.01)
  Age (mean ± SD)              53.01 ± 12.74      53.4 ± 17.74     51.43 ± 16.17     54.32 ± 13.73       54.07 ± 13.81
   \<20                        6,928 (15.32)      5,564 (12.30)    15,015 (33.20)    7,479 (16.54)       3,092 (6.84)
   20--29                      31,458 (32.94)     2,561 (2.68)     35,064 (36.72)    32,134 (33.65)      13,038 (13.65)
   30--39                      156,422 (51.54)    7,447 (2.45)     66,968 (22.06)    130,704 (43.06)     48,151 (15.86)
   40--49                      415,900 (58.29)    17,660 (2.48)    118,228 (16.57)   315,763 (44.25)     124,418 (17.44)
   50--59                      476,338 (54.98)    24,123 (2.78)    142,677 (16.47)   393,807 (45.45)     148,443 (17.13)
   60--69                      251,389 (49.42)    17,004 (3.34)    87,818 (17.26)    241,238 (47.43)     86,640 (17.03)
   70--79                      131,138 (44.49)    11,737 (3.98)    55,469 (18.82)    145,191 (49.26)     54,624 (18.53)
   ≥80                         36,988 (40.38)     4,688 (5.12)     18,133 (19.80)    48,281 (52.71)      18,228 (19.90)
  Sex                                                                                                     
   Male                        904,778 (55.38)    60,192 (3.68)    275,763 (16.88)   775,090 (47.44)     251,286 (15.38)
   Female                      601,783 (46.82)    30,592 (2.38)    263,609 (20.51)   539,507 (41.97)     245,348 (19.09)
  Income                                                                                                  
  Medical aid                  46,315 (41.27)     3,943 (3.51)     27,160 (24.20)    46,751 (41.66)      19,055 (16.98)
   Q1 (low)                    398,887 (52.05)    22,550 (2.94)    139,374 (18.19)   353,498 (46.13)     138,079 (18.02)
   Q2                          363,159 (52.13)    20,640 (2.96)    126,485 (18.16)   315,653 (45.31)     121,217 (17.40)
   Q3                          346,565 (52.23)    21,268 (3.21)    119,086 (17.95)   299,447 (45.13)     111,549 (16.81)
   Q4 (high)                   351,635 (51.68)    22,383 (3.29)    127,267 (18.7)    299,248 (43.98)     106,734 (15.69)
  Residence                                                                                               
   Metropolitan                909,496 (52.23)    53,311 (3.06)    320,725 (18.42)   778,121 (44.69)     282,095 (16.20)
   City                        430,908 (51.68)    25,320 (3.04)    156,480 (18.77)   375,042 (44.98)     148,404 (17.80)
   Rural                       166,157 (48.29)    12,153 (3.53)    62,167 (18.07)    161,434 (46.92)     66,135 (19.22)
  Charlson comorbidity index                                                                              
   0                           502,861 (53.60)    12,245 (1.31)    137,490 (14.66)   456,193 (48.63)     163,131 (17.39)
   1                           411,171 (51.96)    18,536 (2.34)    136,449 (17.24)   355,466 (44.92)     138,614 (17.52)
   2                           252,680 (50.79)    19,096 (3.84)    97,293 (19.56)    212,683 (42.75)     85,095 (17.10)
   ≥3                          339,849 (49.10)    40,907 (5.91)    168,140 (24.29)   290,255 (41.94)     109,794 (15.86)
  Comorbidity                                                                                             
   Diabetes                    240,501 (64.74)    21,283 (5.73)    53,265 (14.34)    127,538 (34.33)     55,124 (14.84)
   Dyslipidemia                465,523 (57.74)    44,577 (5.53)    155,768 (19.32)   331,832 (41.16)     124,074 (15.39)
   Congestive heart failure    45,540 (37.71)     22,783 (18.87)   65,416 (54.18)    37,246 (30.85)      16,936 (14.03)
   Ischemic heart failure      148,348 (36.94)    40,612 (10.11)   161,776 (40.29)   178,876 (44.55)     44,121 (10.99)
   Stroke                      67,621 (49.88)     6,568 (4.84)     34,636 (25.55)    66,925 (49.37)      19,360 (14.28)
   Chronic kidney disease      16,310 (59.82)     2,274 (8.34)     5,974 (21.91)     12,220 (44.82)      3,257 (11.95)
   Cancer                      13,353 (29.92)     1,531 (3.43)     11,312 (25.35)    24,520 (54.95)      4,385 (9.83)
  Provider type                                                                                           
   General hospital            350,910 (37.95)    67,357 (7.29)    316,088 (34.19)   406,074 (43.92)     81,064 (8.77)
   Hospital                    161,403 (48.77)    5,958 (1.80)     57,090 (17.25)    176,623 (53.37)     55,586 (16.80)
   Clinic                      946,054 (60.62)    14,843 (0.95)    160,542 (10.29)   668,985 (42.86)     339,547 (21.76)
   Others                      48,194 (46.82)     2,626 (2.55)     5,652 (5.49)      62,915 (61.12)      20,437 (19.85)
  Year                                                                                                    
   2011                        312,074 (49.75)    21,853 (3.48)    115,374 (18.39)   291,626 (46.49)     132,317 (21.09)
   2012                        306,353 (51.24)    20,206 (3.38)    112,748 (18.86)   257,977 (43.15)     117,653 (19.68)
   2013                        300,076 (51.87)    18,703 (3.23)    104,476 (18.06)   252,941 (43.73)     94,175 (16.28)
   2014                        280,036 (52.01)    15,514 (2.88)    101,408 (18.83)   245,769 (45.64)     76,045 (14.12)
   2015                        308,022 (53.38)    14,508 (2.51)    105,366 (18.26)   266,284 (46.15)     76,444 (13.25)

[^1]: Academic Editor: Tomohiro Katsuya
